Research Article| Volume 96, ISSUE 4, SUPPLEMENT , 67-69, August 22, 2005

Download started.


Role of Low-Density Lipoprotein Apheresis

      Low-density lipoprotein (LDL) apheresis has been shown to reduce plasma levels of total cholesterol, LDL cholesterol, and lipoprotein(a). In addition to these lipoprotein changes, LDL apheresis induces atherosclerosis regression, improves myocardial perfusion and endothelial function, and may reduce cardiovascular event rates.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP-III)
        Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP-III). National Institutes of Health, Bethesda, MD2002: VI-1-VI-4 (NIH Publication No. 02-5215.)
        • Vella A.
        • Pineda A.
        • O’Brien T.
        Low density lipoprotein apheresis for the treatment of refractory hyperlipidemia.
        Mayo Clin Proc. 2001; 76: 1039-1046
        • Gordon B.
        • Stein E.
        • Jones P.
        • Illingworth D.R.
        Indications for LDL apheresis.
        Am J Cardiol. 1994; 74: 1109-1112
        • Lane D.
        • Alaupovic P.
        • Knight-Gibson C.
        • Dudley V.
        • Laughlin L.
        Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal LDL precipitation treatments.
        Am J Cardiol. 1995; 75: 1124-1129
        • Seidel D.
        H.E.L.P apheresis therapy in the treatment of severe hypercholesterolemia.
        Artif Organs. 1996; 20: 303-310
        • Schuff-Werner P.
        • Gohlke H.
        • Bartmann U.
        • Baggio G.
        • Corti M.
        • Dinsenbacher A.
        • Eiseahaver T.
        • Grontzmacher P.
        • Kelker C.
        • Kettner U.
        • et al.
        The H.E.L.P. LDL apheresis multinational study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease.
        Eur J Clin Invest. 1994; 24: 724-732
        • Kroon A.
        • van Asten W.
        • Stalenhoef A.
        Effect of apheresis of LDL in peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
        Ann Intern Med. 1996; 125: 945-954
        • Nishimura S.
        • Sekiguchi M.
        • Kano T.
        • Ishiwata S.
        • Nagasaki F.
        • Nishiae T.
        • Okimoto T.
        • Kutsumi Y.
        • Kuwabara Y.
        • Takatsu F.
        • et al.
        Effects of intensive lipid lowering by LDL apheresis on regression of coronary atherosclerosis in patients with familial hyperlipidemia.
        Atherosclerosis. 1999; 144: 409-417
        • Matsuzaki M.
        • Hiramori K.
        • Imaizumi T.
        • Kitabatake A.
        • Hishida H.
        • Nomura N.
        • Fuji T.
        • Sakuma I.
        • Fukami K.
        • Honda T.
        • et al.
        Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein apheresis in familial hyperlipidemia.
        J Am Coll Cardiol. 2002; 40: 220-227
        • Waters D.
        • Higginson L.
        • Gladstone P.
        • Kimball B.
        • Le May M.
        • Boccuzzi S.
        • Lesperance J.
        Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative angiography.
        Circulation. 1994; 89: 959-968
        • Nissun S.E.
        • Tuzcu E.M.
        • Schoenhagen P.
        • Brown B.G.
        • Ganz P.
        • Vogel R.A.
        • Crowe T.
        • Howard G.
        • Cooper C.J.
        • Brodie B.
        • et al.
        • Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) investigators
        Effects of intensive compared with moderate lipid lowering therapy on the progression of coronary atherosclerosis.
        JAMA. 2004; 291: 1071-1080
        • Mellwig K.
        • Baller D.
        • Gleichmann U.
        • Moll D.
        • Betker S.
        • Weiss R.R.
        • Notohamiprodjo G.
        Improvement of coronary vasodilation capacity through a single LDL apheresis.
        Atherosclerosis. 1998; 139: 173-178
        • Sampietro T.
        • Bigazzi F.
        • DalPino B.
        • Fusaro S.
        • Sassi G.
        • Marchetti C.C.
        • Sambuccti G.
        • Tuomi M.
        • Pandi O.
        • Bionda A.
        Improvement of myocardial blood flows by single LDL apheresis assessed with PET. 2000 (Presented at the International Symposium on Atherosclerosis; June 25–29; Stockholm, Sweden. Abstract WeP35:W26.)
        • Tamai O.
        • Matsuka H.
        • Itabe H.
        • Wada Y.
        • Kohno K.
        • Imaizumi T.
        Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans.
        Circulation. 1997; 95: 76-82
        • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
        Prevention of coronary heart disease events and death with pravastatin in patients with coronary heart disease and a range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Scandinavian Simvastatin Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.
        Lancet. 1994; 344: 1383-1389
        • Mabuchi H.
        • Koizumi J.
        • Shimizu M.
        • Kajinami K.
        • Miyamoto K.
        • Ueda K.
        • Takegoshi T.
        Long term efficacy of low density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia.
        Am J Cardiol. 1998; 82: 1489-1495
        • Gordon B.
        • Kelsey S.
        • Dau P.
        • Gotto A.
        • Graham Y.
        • Illingworth R.
        • Isaacson J.
        • Jones P.
        • Letman S.
        • Saal S.
        • et al.
        Long term effects of LDL apheresis using automated dextran sulfate cellulose adsorption system.
        Am J Cardiol. 1998; 81: 407-411